Northern Trust Corp increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 29.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 598,626 shares of the biopharmaceutical company’s stock after acquiring an additional 134,463 shares during the quarter. Northern Trust Corp owned approximately 0.97% of TG Therapeutics worth $6,016,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Legal & General Group Plc lifted its stake in shares of TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 384 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 1,395 shares in the last quarter. UBS Group AG lifted its stake in shares of TG Therapeutics by 34.4% in the first quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 3,736 shares in the last quarter. HighTower Advisors LLC acquired a new position in shares of TG Therapeutics in the first quarter worth about $170,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of TG Therapeutics in the second quarter worth about $156,000. Institutional investors and hedge funds own 49.58% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “TG Therapeutics, Inc. (TGTX) Position Lifted by Northern Trust Corp” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/11/15/tg-therapeutics-inc-tgtx-position-lifted-by-northern-trust-corp.html.
Shares of TG Therapeutics, Inc. (NASDAQ TGTX) opened at $8.65 on Wednesday. TG Therapeutics, Inc. has a fifty-two week low of $4.10 and a fifty-two week high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.05). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. analysts expect that TG Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.
Several research analysts recently commented on TGTX shares. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research cut TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. ValuEngine cut TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $33.00 price target (up previously from $18.00) on shares of TG Therapeutics in a research note on Tuesday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $26.78.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.